67 assets in Mixed Phenotype Acute Leukemia

Therapeutic assets addressing Mixed Phenotype Acute Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Daunomycin Mixed Phenotype Acute Leukemia	St. Jude Children's Research Hospital	P4	BB (67)
Cytarabine Mixed Phenotype Acute Leukemia	Children's Oncology Group	P4	BB (66)
Dexasone Mixed Phenotype Acute Leukemia	St. Jude Children's Research Hospital	P4	BB (66)
Etoposide Mixed Phenotype Acute Leukemia	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	P3	BB (66)
Hydrocortisone Mixed Phenotype Acute Leukemia	Children's Oncology Group	P4	BB (65)
Methotrexate Mixed Phenotype Acute Leukemia	Children's Oncology Group	P4	BB (64)
Treosulfan Mixed Phenotype Acute Leukemia	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	P2/3	BB (64)
Calaspargase Pegol Mixed Phenotype Acute Leukemia	St. Jude Children's Research Hospital	P3	B (63)
Cyclophosphamide Mixed Phenotype Acute Leukemia	St. Jude Children's Research Hospital	P3	B (63)
Nivestim Mixed Phenotype Acute Leukemia	Fred Hutchinson Cancer Center	P3	B (63)
Orca-T Mixed Phenotype Acute Leukemia	Orca Biosystems, Inc.	P3	B (63)
(+)-Vincristine Mixed Phenotype Acute Leukemia	St. Jude Children's Research Hospital	P4	B (63)
Fludarabine Mixed Phenotype Acute Leukemia	Fred Hutchinson Cancer Center	P3	B (62)
Prednisolone Mixed Phenotype Acute Leukemia	Children's Oncology Group	P3	B (62)
Adriamycin Mixed Phenotype Acute Leukemia	St. Jude Children's Research Hospital	P3	B (61)
Idarubicin Mixed Phenotype Acute Leukemia	Fred Hutchinson Cancer Center	P2	B (61)
Pegaspargase Mixed Phenotype Acute Leukemia	Children's Oncology Group	P3	B (61)
Prednisone Mixed Phenotype Acute Leukemia	St. Jude Children's Research Hospital	P3	B (61)
Busulfanum Mixed Phenotype Acute Leukemia	Fred Hutchinson Cancer Center	P3	B (60)
Mitoxantrone Mixed Phenotype Acute Leukemia	University of Washington	P2	B (60)
Rituximab Mixed Phenotype Acute Leukemia	Children's Oncology Group	P3	B (60)
Tacrolimus Mixed Phenotype Acute Leukemia	Children's Oncology Group	P3	B (60)
Venetoclax Mixed Phenotype Acute Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2	B (60)
Azacitidine Mixed Phenotype Acute Leukemia	Therapeutic Advances in Childhood Leukemia Consortium	P2	B (59)
Blinatumomab Mixed Phenotype Acute Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P3	B (59)
Cyclosporin A Mixed Phenotype Acute Leukemia	Fred Hutchinson Cancer Center	P2	B (59)
Mercaptopurine Anhydrous Mixed Phenotype Acute Leukemia	St. Jude Children's Research Hospital	P3	B (59)
Revumenib Mixed Phenotype Acute Leukemia	Children's Oncology Group	P2	B (59)
Thioguanine Anhydrous Mixed Phenotype Acute Leukemia	St. Jude Children's Research Hospital	P3	B (59)
Vincristine Sulfate Mixed Phenotype Acute Leukemia	Children's Oncology Group	P3	B (59)
Thiotepa Mixed Phenotype Acute Leukemia	Fred Hutchinson Cancer Center	P3	B (58)
Decitabine Mixed Phenotype Acute Leukemia	Fred Hutchinson Cancer Center	P2	B (57)
Melphalan Mixed Phenotype Acute Leukemia	Children's Oncology Group	P3	B (57)
Mesna Mixed Phenotype Acute Leukemia	Center for International Blood and Marrow Transplant Research	P2	B (57)
Vorinostat Mixed Phenotype Acute Leukemia	Johns Hopkins All Children's Hospital	P2	B (56)
Dasatinib Mixed Phenotype Acute Leukemia	St. Jude Children's Research Hospital	P2	CCC (54)
Dexrazoxane Mixed Phenotype Acute Leukemia	Children's Oncology Group	P3	CCC (54)
Flumatinib Mixed Phenotype Acute Leukemia	The First Affiliated Hospital of Soochow University	P2	CCC (54)
Imatinib Mixed Phenotype Acute Leukemia	Children's Oncology Group	P3	CCC (54)
Inotuzumab Ozogamicin Mixed Phenotype Acute Leukemia	Children's Oncology Group	P3	CCC (54)
Isocyclophosphamide Mixed Phenotype Acute Leukemia	Children's Oncology Group	P3	CCC (54)
Levofolinic Acid Mixed Phenotype Acute Leukemia	Children's Oncology Group	P3	CCC (54)
Bortezomib Mixed Phenotype Acute Leukemia	St. Jude Children's Research Hospital	P2	CCC (53)
Cladribine Mixed Phenotype Acute Leukemia	University of Washington	P1/2	CCC (51)
Nadravaleucel Mixed Phenotype Acute Leukemia	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	P2	CCC (51)
Nelarabine Mixed Phenotype Acute Leukemia	St. Jude Children's Research Hospital	P2	CCC (50)
Cobicistat Mixed Phenotype Acute Leukemia	Syndax Pharmaceuticals	P1/2	CCC (48)
Imgn632 Mixed Phenotype Acute Leukemia	Fred Hutchinson Cancer Center	P1/2	CCC (48)
Itraconazole Mixed Phenotype Acute Leukemia	Kura Oncology, Inc.	P1/2	CCC (48)
Lapine T-Lymphocyte Immune Globulin Mixed Phenotype Acute Leukemia	Children's Oncology Group	P3	CCC (48)

Showing 1 to 50 of 67 assets

PreviousPage 1 of 2Next